These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 22183214)

  • 1. Synthetic conjugated estrogens-B and postmenopausal nocturnal vasomotor symptoms: a randomized controlled trial.
    Liu JH; Reape KZ; Hait HI
    Obstet Gynecol; 2012 Jan; 119(1):78-84. PubMed ID: 22183214
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transition from estrogen-progestin to raloxifene in postmenopausal women: effect on vasomotor symptoms.
    Gordon S; Walsh BW; Ciaccia AV; Siddhanti S; Rosen AS; Plouffe L
    Obstet Gynecol; 2004 Feb; 103(2):267-73. PubMed ID: 14754694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens.
    Utian WH; Lederman SA; Williams BM; Vega RY; Koltun WD; Leonard TW
    Obstet Gynecol; 2004 Feb; 103(2):245-53. PubMed ID: 14754691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lowest effective transdermal 17beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial.
    Bachmann GA; Schaefers M; Uddin A; Utian WH
    Obstet Gynecol; 2007 Oct; 110(4):771-9. PubMed ID: 17906008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women.
    Utian W; Yu H; Bobula J; Mirkin S; Olivier S; Pickar JH
    Maturitas; 2009 Aug; 63(4):329-35. PubMed ID: 19647382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perimenopausal women in estrogen vasomotor trials: contribution to placebo effect and efficacy outcome.
    Simon JA; Stevens RE; Ayres SA; Phelps KV
    Climacteric; 2001 Mar; 4(1):19-27. PubMed ID: 11379374
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative controlled trial of a novel oral estrogen therapy, estradiol acetate, for relief of menopause symptoms.
    Utian WH; Speroff L; Ellman H; Dart C
    Menopause; 2005; 12(6):708-15. PubMed ID: 16278614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial.
    Speroff L; Gass M; Constantine G; Olivier S;
    Obstet Gynecol; 2008 Jan; 111(1):77-87. PubMed ID: 18165395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women.
    Simon JA; Reape KZ; Wininger S; Hait H
    Fertil Steril; 2008 Oct; 90(4):1132-8. PubMed ID: 18053998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week clinical trial determining the efficacy of synthetic conjugated estrogens, A (SCE), in the treatment of vasomotor symptoms in menopausal women.
    Stevens RE; Hanford K; Wason S; Cusack SL; Phelps KV
    Int J Fertil Womens Med; 2000; 45(4):264-72. PubMed ID: 10997482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial.
    Reddy SY; Warner H; Guttuso T; Messing S; DiGrazio W; Thornburg L; Guzick DS
    Obstet Gynecol; 2006 Jul; 108(1):41-8. PubMed ID: 16816054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy.
    Prior JC; Nielsen JD; Hitchcock CL; Williams LA; Vigna YM; Dean CB
    Clin Sci (Lond); 2007 May; 112(10):517-25. PubMed ID: 17419685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tibolone for the treatment of moderate to severe vasomotor symptoms and genital atrophy in postmenopausal women: a multicenter, randomized, double-blind, placebo-controlled study.
    Swanson SG; Drosman S; Helmond FA; Stathopoulos VM
    Menopause; 2006; 13(6):917-25. PubMed ID: 17006377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
    Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
    Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hot flush symptom-free days with bazedoxifene/conjugated estrogens in postmenopausal women.
    Yu H; Racketa J; Chines AA; Mirkin S
    Climacteric; 2013 Apr; 16(2):252-7. PubMed ID: 23035721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying meaningful differences in vasomotor symptoms among menopausal women.
    Wyrwich KW; Spratt DI; Gass M; Yu H; Bobula JD
    Menopause; 2008; 15(4 Pt 1):698-705. PubMed ID: 18369313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of estrogen-androgen and estrogen-only therapy on vasomotor symptoms, gonadotropin secretion, and endogenous androgen bioavailability in postmenopausal women.
    Simon J; Klaiber E; Wiita B; Bowen A; Yang HM
    Menopause; 1999; 6(2):138-46. PubMed ID: 10374221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estradiol in micellar nanoparticles: the efficacy and safety of a novel transdermal drug-delivery technology in the management of moderate to severe vasomotor symptoms.
    Simon JA;
    Menopause; 2006; 13(2):222-31. PubMed ID: 16645536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.